Research programme: neuromuscular disorder therapeutics - Ipsen/Pharnext
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pharnext
- Developer Ipsen; Pharnext
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Charcot-Marie-Tooth disease; Neuromuscular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Charcot-Marie-Tooth-disease in France
- 16 Jul 2016 No recent reports of development identified for research development in Neuromuscular-disorders in France
- 15 Jun 2009 Early research in Neuromuscular disorders in France (unspecified route)